MET and hypertensive disorder: Toxicities seen with vandetanib included diarrhea, rash, nausea, hypertension, and headache (16) and patients who received cabozantinib, which inhibits hepatocyte growth factor receptor (MET) and VEGFR2 in addition to RET often experienced diarrhea, palmar-plantar erythrodysesthesia, decreased weight and appetite, nausea, and fatigue (17).